German China India

The Netherlands: Biopharmaceuticals

Halix to Start Operational Production at New cGMP Facility

| Editor: Alexander Stark

The new cGMP facility will be starting operational production in Q4-2019.
Gallery: 1 image
The new cGMP facility will be starting operational production in Q4-2019. (Source: Halix)

Halix, a contract development and manufacturing organization of clinical and commercial proteins and viral products, based in the Netherlands, announced the interim delivery of a new 6,700 m2 cGMP facility in Leiden Bio Science Park.

Leiden/The Netherlands — Following one year of construction, Halix has completed its new state-of-the-art cGMP facility for the development and production of biopharmaceutical drug substances.

The new five-level production facility contains a state-of-the-art manufacturing line for viral vaccines and viral vectors and a separate protein manufacturing area with a capacity up to 1,000 Liter single-use bioreactors. In addition, lab space is available for process development, analytical development and quality control. All cleanroom areas have a unidirectional process flow and are designed to allow commercial manufacturing of biopharmaceuticals products.

Comments are being loaded ....

Leave a comment

The comment is checked by an editor and will be released soon.

  1. Avatar
    Avatar
    Edited by at
    Edited by at
    1. Avatar
      Avatar
      Edited by at
      Edited by at

Comments are being loaded ....

Report comment

Kommentar Freigeben

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

Freigabe entfernen

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

copyright

This article is protected by copyright. You want to use it for your own purpose? Infos can be found under www.mycontentfactory.de (ID: 46074484 / Pharma & Food)